Augustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Lead Candidate into Clinical Development for Neurological Diseases

Augustine Therapeutics, a pioneering biotech firm dedicated to advancing treatments for neurodegenerative and cardiometabolic diseases, has successfully closed its Series A funding round with EUR 17 million (USD 18.5 million).…

Read MoreAugustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Lead Candidate into Clinical Development for Neurological Diseases

Cayuga Biotech Accelerates Life-Saving Hemorrhage Treatment with PolyP-SNP Complex, Promising 12x Faster Coagulation

Cayuga Biotech introduced groundbreaking preclinical findings today on its innovative polyphosphate (polyP)-based therapy aimed at combating life-threatening hemorrhage. The study revealed that the polyP-SNP (silica nanoparticle) complex accelerates thrombin production…

Read MoreCayuga Biotech Accelerates Life-Saving Hemorrhage Treatment with PolyP-SNP Complex, Promising 12x Faster Coagulation